ClinicalTrials.gg
CompletedNCT03333668AGUALISUpdated Aug 12, 2026

Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

An interventional study of Lisdexamfetamine dimesylate and Guanfacine Extended Release Oral Tablet in ADHD, sponsored by King's College London. Completed at 1 site in United Kingdom. Open to participants aged 8 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by King's College London · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
8 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
38th of 51
25 · median 48
Started
2018
with 2 others
No phase
5 of 51
none open now
Registered
48th of 51
by date

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 38th largest by enrollment, is one of 3 that started in 2018, is one of 5 with no phase, and was the 48th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 8 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This is not a clinical trial. The aim of this study is to understand the mechanism of action of two recently licensed drugs for ADHD on brain function. The investigators will compare the brain activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by placebo in 20 drug-free patients with ADHD using functional Magnetic Resonance Imaging (fMRI). For this purpose the investigators intend to scan participants during their performance of tasks of attention, working memory, and inhibition, which the investigators know from previous studies to elicit abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).

Read the detailed description

Twenty ADHD patients between 8 and 20 years of age will participate in the double-blind, randomised, active drug condition, within-group, placebo-controlled experimental fMRI study. Each participant will be assessed in baseline measures during a pre-assessment visit. Then the patient will be scanned 3 times under each of these 3 drug conditions: GXR, LISDEX, and placebo. Every patient will receive a single typical clinical weight-adjusted dose of GXR (0.05mg/kg rounded down to the closest dose of 1mg, 2mg, or a maximum of 3mg), LISDEX (for participants aged 8-9 years 20mg regardless of weight; for participants aged 10-20 years the dose will be calculated at 0.5mg/kg rounded to the closest 30, 40, or 50mg, middle doses, e.g. 35mg, will be rounded down) and placebo (10mg Vit C) in one of the scans, in a randomised order. Patients will perform a battery of cognitive tests 3.5 hours after drug administration, after which the will undergo an fMRI scan. The scan will start 4.5 hours after drug administration where drugs have shown to have maximum plasma concentration. Participants will be scanned 3 times, one week apart, under each drug condition.

Substantial amendment submitted on 11/09/2019 regarding dosage:

Lowering the dose of lisdexamfetamine

The investigators had two participants who experienced transient minor adverse events after the single dose of Lisdexamfetamine.Therefore, the investigators have decided to lower the doses of lisdexamfetamine given in this study. Our original doses of lisdexamfetamine (30mg for participants under 30kg of body weight, 50mg for participants over 30kg of body weight) were weight adjusted and based on consultations with child psychiatrists, as well as on published studies using single doses of lisdexamfetamine. IN view of the adverse events our expert in paediatric psychopharmacology, Prof Paramala Santosh, has recommended the following rules for determining dosages of lisdexamfetamine in order to avoid any more adverse events:

  • Ages 8-9 years - will receive 20mg (regardless of weight)
  • Ages 10-20 years - will receive a minimum dose of 30mg or if higher than 60kg, a weight-adjusted dose at 0.5mg/kg which will be rounded down to the closest 30, 40, or 50mg (middle doses, e.g. 35mg, will be rounded down). The maximum dose will always be 50mg.
03

Conditions studied

  • ADHD

Keywords

  • Lisdexamfetamine
  • Guanfacine
  • functional Magnetic Resonance Imaging
  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
8 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: 8-20 years
  • Medication-naïve or non-medicated for two weeks or on stimulant medication, and willing to take the medication off for 48 hours before scans.
  • Meeting diagnosis of ADHD
  • Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)
  • Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating Scales, CPRS (Conners et al., 2008)
  • Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)
  • IQ > 70 as tested on the WASI-II (Wechsler et al., 1999)
  • Mood and depression symptoms will be allowed as long as they are not the primary diagnosis.

Exclusion criteria

Exclusion Criteria:

  • IQ \< 70 (Wechsler et al., 1999).
  • Comorbidity with schizophrenia, bipolar disorder, learning disability, OCD, severe depression with current suicidal behaviour (as assessed by a clinical interview)
  • Neurological problems, i.e. a history of severe neurological illness, e.g. brain tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc.
  • Substance abuse history
  • Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data integrity or safety of the subject (i.e. to any of the treatments) as determined by the investigators
  • Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker, implanted medication pumps, neural stimulators, claustrophobia
  • Unable to give informed assent or consent in the case of the parent
  • Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated states, hyperexcitability, hyperthyroidism, moderate or severe hypertension, symptomatic cardiovascular disease)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Lisdexamfetamine - Placebo

    Drug: Lisdexamfetamine dimesylate · Drug: Placebo

  • Active comparator
    Guanfacine - Placebo

    Drug: Guanfacine Extended Release Oral Tablet · Drug: Placebo

  • Experimental
    Lisdexamfetamine - Guanfacine

    Drug: Lisdexamfetamine dimesylate · Drug: Guanfacine Extended Release Oral Tablet

Interventions

  • Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

    Also known as: Vyvanse (Shire Pharmaceuticals Ltd.)

  • Guanfacine Extended Release (0.05mg/kg) tablet

    Also known as: Intuniv (Shire Pharmaceuticals Ltd.)

  • DrugPlacebo

    Vitamin C (10mg) tablet

06

What researchers measure

Primary outcomes

  1. Change in brain activation under the three drug conditions (LISDEX, GXR, placebo)

    Brain activation as measured by blood-oxygen-level-dependent (BOLD) response obtained by fMRI for each of the 3 below listed tasks and functional connectivity measures for the resting state scan. 1. A working memory task (N-back) 2. A tracking stop task 3. A parametric sustained attention task

    Time frame: 2 weeks (3 hourly scans one week apart)

Secondary outcomes

  1. Changes in dependent variables extracted from performance on the fMRI tasks used under the three drug conditions (LISDEX, GXR, placebo)

    1. A working memory task (N-back) 2. A tracking stop task 3. A parametric sustained attention task

    Time frame: 2 weeks (3 hourly scans one week apart)

  2. Changes in dependent variables extracted from performance on a task battery outside the MRI scanner

    Gonogo task, Simon task, Continuous performance task, Vigilance task, Time Discrimination task

    Time frame: 2 weeks (3 sessions one week apart)

07

Study locations

1 site
  • Institute of Psychiatry, Psychology & Neuroscience; King's College London
    London, SE5 8AF, United Kingdom
08

References and documents

Publications

  • Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry. 2005 Jun;162(6):1067-75. doi: 10.1176/appi.ajp.162.6.1067. PubMed 15930054 ↗
  • Smith AB, Taylor E, Brammer M, Toone B, Rubia K. Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am J Psychiatry. 2006 Jun;163(6):1044-51. doi: 10.1176/ajp.2006.163.6.1044. PubMed 16741205 ↗
  • El Masri S, Kowalczyk OS, Chiu TH, Criaud M, Lukito S, Mazibuko N, Salazar de Pablo G, Perez Rodriguez V, Makos O, Lam SL, Westwood S, Eaton-Turner A, Bozhilova N, Conti A, Santosh P, Roessner V, Kohls G, Mehta MA, Rubia K. Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD. Front Psychiatry. 2025 Nov 3;16:1676472. doi: 10.3389/fpsyt.2025.1676472. eCollection 2025. PubMed 41256939 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2024, 71 months.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 71 months is above that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 7, 2017
StartActual
Oct 1, 2018
Primary completionActual
Sep 6, 2024
CompletionActual
Sep 7, 2024
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03333668
Collaborators
Shire, Takeda
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Oct 1, 2018
Primary completion
Sep 6, 2024
Completion
Sep 7, 2024
Last update
Aug 12, 2026

Study contacts

Katya Rubia, PhD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lisdexamfetamine · Guanfacine

Start the discussion